Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of fixed-dose darunavir/cobicistat/emtricitabine/tenofovir alafenamide versus separate tablets
NL-OMON49227Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of darunavir, cobicistat, emtricitabine and tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum observed analyte concentration, Time to maximum observed analyte concentration and 6 more. Started Jan 2021; status: completed.
02
Drugs
darunavircobicistatemtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON49227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49227.